Home › Cervical Cancer › Oklahoma › Tulsa
Cervical Cancer clinical trials in Tulsa, OK
4 studies for Cervical Cancer are looking for participants at sites in and around Tulsa (within about 30 miles). Open a study to see who can join and how to contact the study team.
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
RecruitingPhase 4
- Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
RecruitingPhase 3
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001), Tulsa
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
RecruitingPhase 1/2
- Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Tulsa
About Cervical Cancer
Cervical cancer starts in the cells of the cervix, which is the lower, narrow end of the uterus. Long-lasting HPV infection causes almost all cervical cancers.
More about Cervical Cancer on MedlinePlus
Cervical Cancer trials in other cities
- Houston, TX33 studies
- New York City, NY19 studies
- Nashville, TN19 studies
- Boston, MA18 studies
- Los Angeles, CA16 studies
- Arlington, VA16 studies
- San Antonio, TX14 studies
- Dallas, TX13 studies
- St. Louis, MO13 studies
- Orlando, FL12 studies
- Chicago, IL12 studies
- Columbus, OH11 studies
Other studies in Tulsa
- Heart Failure9 studies
- Overweight6 studies
- Ischemic Stroke5 studies
- Melanoma5 studies
- Obesity5 studies
- Cancer (all types)4 studies
- Non-Small Cell Lung Cancer4 studies
- Parkinson's Disease4 studies
- COPD4 studies
- Breast Cancer4 studies
- Depression4 studies
- Aortic Valve Stenosis4 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.